Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: BioNTech SE

Market Cap 20.03B 22.97B 18.55B 17.36B 32.56B 2,167B 32.76B 220B 85.28B 1,067B 86.22B 84.37B 3,704B P/E 2026 *
-18x
P/E 2027 * -17.7x
Enterprise Value 9.17B 10.52B 8.5B 7.95B 14.92B 993B 15.01B 101B 39.07B 489B 39.5B 38.65B 1,697B EV / Sales 2026 *
4.24x
EV / Sales 2027 * 4.82x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 week+1.09%
Current month-4.26%
1 month+4.17%
3 months+2.21%
6 months-0.06%
Current year-3.14%
1 week 76.7
Extreme 76.7
81.35
1 month 73.2
Extreme 73.2
84.9
3 years 68.35
Extreme 68.35
124.7
5 years 68.35
Extreme 68.35
397
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.02%+1.09%-12.11%-23.54% 22.98B
+2.15%+3.89%+69.70%+117.79% 55.19B
+4.60%+3.02%+57.38%+62.27% 45.75B
+1.80%+1.71%-5.97%+387.36% 20.76B
-0.26%-0.58%+25.47%-18.57% 16.26B
+0.55%+3.42%+21.84%-36.69% 15.42B
-1.57%-2.36%+19.32%+160.31% 13.05B
+4.95%+11.70%+125.78%+261.94% 12.45B
-5.63%-6.39%+19.78% - 12.37B
+0.30%+1.53%+79.29%+108.46% 11.66B
Average +0.79%+2.85%+40.05%+113.26% 22.55B
Weighted average by Cap. +1.73%+1.80%+43.42%+105.85%

Financials

2026 *2027 *
Net sales 2.17B 2.48B 2.01B 1.88B 3.52B 234B 3.54B 23.8B 9.22B 115B 9.32B 9.12B 401B 2.23B 2.56B 2.07B 1.93B 3.63B 241B 3.65B 24.51B 9.5B 119B 9.6B 9.4B 413B
Net income -1.05B -1.21B -973M -911M -1.71B -114B -1.72B -11.55B -4.47B -55.98B -4.52B -4.43B -194B -1.17B -1.34B -1.08B -1.01B -1.89B -126B -1.91B -12.8B -4.96B -62.08B -5.02B -4.91B -216B
Net Debt -10.85B -12.45B -10.05B -9.41B -17.65B -1,174B -17.75B -119B -46.21B -578B -46.72B -45.72B -2,007B -9.28B -10.64B -8.6B -8.05B -15.09B -1,004B -15.18B -102B -39.52B -494B -39.96B -39.1B -1,717B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Date Price Change
22/06/26 79.55 +1.02%
19/06/26 78.75 -0.57%
18/06/26 79.20 -1.19%
17/06/26 80.15 +3.55%
16/06/26 77.40 -1.34%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
79.19EUR
Average target price
106.75EUR
Spread / Average Target
+34.80%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!